HYDERABAD: Hyderabad bagged yet another major investment in the vaccine manufacturing sector with Indian Immunologicals Ltd (IIL) on Monday announcing that it would invest Rs 700 crore to set up a new animal vaccine manufacturing facility in Genome Valley in the city outskirts.
The company said the facility, which will hire 750 employees, would help meet the vaccine security of the nation against economically important diseases like foot and mouth disease (FMD) and other emerging diseases.
Dr K. Anand Kumar and other members of the executive leadership team of IIL including senior vice-presidents Mukul Gaur and N.S.N. Bhargav met industries minister K.T. Rama Rao to announce the company's investment plans.
"Hyderabad is already regarded as the vaccine capital of the world and this expansion further advances its contribution in terms of global health, not just for humans but also for animals," Rama Rao said in a media statement.
IIL, a subsidiary of NDDB, is the leading supplier of FMD vaccine to the National Animal Disease Control Programme (NADCP).
IIL's new facility in Genome Valley Phase 3 will add another 300 million doses per annum of FMD vaccine to its capacity. The existing facility in Gachibowli presently has a capacity of 300 million doses. Production is scheduled to commence in the third year.
